Comment from CYTOKINETICS INCORPORATED
AnonymousSupportBusiness
Summary: Cytokinetics Inc. supports the FDA's request for comments on modernizing the SUPAC-IR and SUPAC-MR guidances. They argue that the current framework is outdated and overly prescriptive, and they recommend transitioning to a science- and risk-based approach that aligns with modern ICH quality frameworks to reduce regulatory burden while maintaining safety.
Cytokinetics appreciates FDA's decision to solicit public comment on the SUPAC-IR and SUPAC-MR guidances. These guidances have served the pharmaceutical industry well by providing a valuable and structured framework for assessing and reporting post-approval manufacturing and formulation changes for more than 3 decades. However, the guidances were developed during the 1990s, prior to many of the scientific and regulatory advancements that now underpin pharmaceutical development and lifecycle management. Since their publication, the regulatory paradigm has evolved significantly toward science- and risk-based decision making through the implementation of ICH Q8 (Pharmaceutical Development), ICH Q9 (Quality Risk Management), ICH Q10 (Pharmaceutical Quality System), and more recently ICH Q12 (Pharmaceutical Product Lifecycle Management). Pharmaceutical Industry has gained substantially greater understanding of the relationship between formulation components (e.g., excipient functionality) and process performance, biopharmaceutics, and application to quality risk management. Consequently, there is a timely opportunity to modernize the SUPAC framework to better align regulatory requirements with risk-based approaches leveraging contemporary scientific knowledge while continuing to ensure product quality, safety, and efficacy.
Please see the attached file for detailed comments.